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PERBANDINGAN TAHAP KIRAAN PELEPASAN KREATININA 
ANTARA HIPERTENSI GESTASI DAN IDPERTENSI KRONIK 
SEMASA HAMIL DAN SELEPAS BERSALIN 
ABSTRAK 
Pengenalan: Frekuensi individu yang didiagnosis hipertensi di seluruh dunia kira-kira 
sehingga 10% daripada semua kehamilan, dan ia juga salah satu punca utama morbiditi dan 
kematian semasa kehamilan. Hipertensi semasa hamil boleh menyebabkan komplikasi 
jangka panjang selepas beberapa tahun. Hipertensi semasa mengandung juga sangat 
berkaitan dengan penyakit buah pinggang tahap akhir. Tujuan: Kajian ini membandingkan 
tahap pengurangan kiraan pelepasan kreatinina antara pesakit hipertensi gestasi dan 
hipertensi kronik daripada kehamilan hingga selepas bersalin. Kajian ini bertujuan untuk 
menilai tahap perbezaan min kiraan pelepasan kreatinina dikira dalam kumpulan (hipertensi 
gestasi dan hipertensi kronik), perbezaan min kiraan pelepasan kreatinina antara kumpulan 
tanpa mengira masa dan perbezaan min pelepasan kreatinina dikira antara kumpulan 
berdasarkan masa. Kaedah: Satu kajian prospektif telah dilakukan ke atas pesakit dengan 
hipertensi gestasi dan hipertensi kronik di Hospital Universiti Sains Malaysia. Kajian ini 
membandingkan pengurangan tahap kiraan pelepasan kreatinina di antara pesakit hipertensi 
gestasi dan kronik. Seramai 10 peserta dari setiap kumpulan telah diambil pada trimester 
ketiga kehamilan dari Klinik Obstetrik & Gynecologi, Hospital USM. Peserta kajian telah 
bersetuju dan maklumat peserta telah diambil dari rekod perubatan pada trimester ketiga 
kehamilan. Peserta memgambil darah bagi ujian fungsi buah pinggang untuk setiap temujanji 
xiv 
pada trimester ketiga, enam minggu selepas bersalin dan 12 minggu selepas bersalin. 
Pelepasan kreatinina dikira dengan menggunakan formula "Modification of Diet in Renal 
Disease'. Analisis Kovarians Ukuran Berulang telah digunakan dan pembolehubah berat 
lahir bayi·dan usia gestasi semasa melahirkan telah dikawal. Keputusan: Keputusan kajian 
rnenunjukkan perbezaan yang signiftkan dalam perbandingan I (trimester ketiga kehamilan-
enam minggu selepas bersalin; perbezaan min: 25.99; 95% CI: 19.84, 32.14; p <0.001) dan 
perbandingan 2 (trimester ketiga kehamilan-12 minggu selepas bersalin: perbezaan min: 
23.66; 95% Cl: 9.63, 37.64; p = 0.003) dalam kumpulan hipertensi gestatasi. Semua 
perbandingan masa di kalangan peserta hipertensi kronik adalah signifikan. Terdapat 
perbezaan yang signifikan dalam perbandingan I (trimester ketiga kehamilan-enam minggu 
selepas bersalin; perbezaan min: 27.02; 95% CI: 18.15, 35.90; p <0.00 1 ), perbandingan 2 
(trimester· ketiga kehamilan-12 minggu selepas bersalin: perbezaan min: 28.85; 95o/o CI: 
20.75, 36.96; p <0.001) dan perbandingan 3 (enam minggu selepas bersalin-12 minggu 
selepas bersalin: perbezaan min: 1.83; 95% CI: 0.41, 3.25; p = 0.015). Untuk hasil interaksi, 
terdapat perbezaan yang signiftkan pelepasan kreatinin dikira pada 12 minggu selepas 
bersalin (p = 0.026). Untuk perbandingan lain, tidak ada perbezaan yang signiftkan untuk 
min kiraan pelepasan kreatinina antara dua kumpulan. Apabila membandingkan tahap kiraan 
pelepasan kreatinina daripada trimester ketiga dan 12 minggu selepas bersalin, hipertensi 
kronik menunjukkan kemerosotan tahap kiraan pelepasan kreatinina yang lebih besar dengan 
perbezaan min 28.85 ml I min. Pesakit dengan hipertensi gestatasi mempunyai peningkatan 
dalam kiraan pelepasan kreatinina pada 12 minggu selepas bersalin tetapi tahap kiraan 
pelepasan kreatinin dalam hipertensi kronik cenderung berkurangan 1.83 ml I min pada 12 
minggu selepas bersalin. Kesimpulan: Pemeriksaan berkala semasa postpartum terutamanya 
terhadap fungsi buah pinggang adalah digalakkan di kalangan wanita yang mempunyai 
XV 
sejarah hipertensi semasa mengandung kerana ia adalah salah satu daripada isu penting yang 
perlu dipertimbangkan kerana berisiko untuk mempunyai penyakit buah pinggang beberapa 
tahun selepas mengandung. 
xvi 
A COMPARISON OF THE CALCULATED CREATININE 
CLEARANCE BETWEEN GESTATIONAL HYPERTENSION AND 
CHRONIC HYPERTENSION DURING PREGNANCY TO 
POSTPARTUM 
ABSTRACT 
Introduction: Hypertension is present in approximately up to 10% of all pregnancies 
worldwide., and also one of the leading causes of morbidity and mortality in pregnancy. 
Hypertensive disorders during pregnancy may cause the long-term complications and 
consequences after a decade having hypertension during pregnancy. Hypertensive disorders 
during pregnancy is also highly associated with end-stage renal disease. Objective: This 
study compared the reduction of creatinine clearance level between gestational and chronic 
hypertension patient from pregnancy to post-delivery. This study aimed to assess the level 
of mean difference of calculated creatinine clearance within group (gestational hypertension 
and chronic hypertension), the mean difference of calculated creatinine clearance between 
groups regardless of time and the mean difference of calculated creatinine clearance between 
groups based on time. Methods: A prospective cohort study was performed on patients with 
gestational and chronic hypertension at Hospital Universiti Sains Malaysia. The total of 10 
pregnant mothers from each group were recruited during their third trimester of pregnancy 
from Obstetrics & Gynaecology Clinic of Hospital USM. The patients were consented and 
medical record was reviewed at recruitment (third tritnester). Patients had the blood taking 
of renal function test for every visit at third trimester, six weeks after delivery and 12 weeks 
xvii 
after delivery. The creatinine clearance was calculated by using Modification of Diet in Renal 
Disease formula. Repeated Measure AN COY A analysis was applied with birth weight and 
gestational age at delivery were controlled. Results: For within group analysis, there was a 
significant difference of mean calculated creatinine clearance within gestational hypertension 
and chronic hypertension based on time after controlling potential covariates (birthweight 
and gestational age at delivery) (F=21.59, p=0.002). Multiple comparisons was performed 
with adjusted a based on Bonferroni correction. The results showed that there were 
significant differences in pair 1 (third trimester-six weeks postpartum; mean difference: 
25.99; 95%CI: 19.84, 32.14; p<0.001) and pair2 (third trimester-12 weeks postpartum: mean 
difference: 23.66; 95% CI: 9.63, 37.64; p=0.003) in gestational hypertension group. In the 
meantime, all comparison groups were significant in chronic hypertension participants. 
Multiple comparisons showed that there were significant differences in pair 1 (third 
trimester-six weeks postpartum; mean difference: 27 .02; 95% CI: 18.15, 35.90; p<O.OO 1 ), 
pair 2 (third trimester-12 weeks postpartum: mean difference: 28.85; 95% CI: 20.75, 36.96, 
p<0.001) and pair 3 (six weeks postpartum-12 weeks postpartum: mean difference: 1.83; 
95% CI: 0.41, 3.25; p=0.015). Meanwhile, there was no significant difference of mean 
calculated creatinine clearance between gestational hypertension and chronic hypertension 
(F=l.59, p=0.266) regardless of time. For time-treatment interaction results in repeated 
measure ANOV A analysis, there was no significant difference of mean calculated creatinine 
clearance between groups based on time (F= 0.56, p= 0.579). But, we still proceed to multiple 
comparison to determine if there was a significant difference for each time. From the results, 
there was a significant difference of calculated creatinine clearance at 12 weeks postpartum 
(p=0.023). For other measurement, there was no significant difference of mean creatinine 
clearance between this two groups. When comparing the creatinine clearance from third 
xviii 
trimester to 12 weeks postpartum, chronic hypertension group showed a big reduction of 
calculated creatinine clearance with mean difference of 28.85 ml/min. Patient with 
gestational hypertension had increase in creatinine clearance at 12 weeks postpartum but the 
creatinine clearance level in chronic hypertension tend to decrease by 1.83 mllmin at 12 
weeks postpartum. Conclusion: The regular check-up during postpartum especially on renal 
function is encouraged in \Vomen with a history of hypertensive disorders in pregnancy as it 
is one of the important issues to consider due to the chance of having renal disorder after 
several years of pregnancy. 
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CHAPTER 1 
INTRODUCTION 
1.1 Hypertensive Disorders during Pregnancy 
1.2 Burden of Hypertension Disorder during Pregnancy 
Hypertension is present in approximately up to 10% of all pregnancies worldwide, and 
also one of the leading causes of morbidity and mortality in pregnancy (Duley, 2009). 
Since 200 I, the prevalence of hypertensive disorders has been increasing among delivery 
hospitalizations (Duley, 2009). 
In the United States. the prevalence of hypertension is 5 to I 0% in pregnant women. 
which is the second leading cause of the maternal death (Sibai et al., 2005). According to 
a study that had been done in Kuala Lumpur, 4.41% patients had pregnancy-induced 
hypertension during pregnancy and 7.14% of all pregnancies died from preeclampsia in 
2008 (Ismail, 2008). 
Hypertensive disorders during pregnancy increase up to 15% of maternal mortality in 
both industrialised and developing countries (Arulkumaran et al .• 2004).The outcomes 
that contributes to hypertensive disorders during pregnancy include small for gestational 
age infants, maternal and perinatal mortality, and pretenn labour (Macdonald-Wallis et 
al., 20 12). In the low outcome countries, the leading causes of mortality among 
hypertensive disorders women are pregnancy and childbirth complication (Duley, 2009). 
Otherwise, women with hypertensive disorders will increase the chance of getting acute 
renal failure (Mehrabadi et al., 2014). 
1 
1.2 Prevalence of Kidney Diseases among Hypertensive Pregnant Women 
Many studies reported long-term complications and consequences after a decade having 
hypertension during pregnancy (Nisell eta/., 1995; Mannisto eta/., 2013a; Asad and 
Garovic, 2014). Women with chronic hypertension contribute a leading factor of getting 
preeclampsia during pregnancy that can cause chronic kidney disease (Szczech eta/., 
2014 ). The previous researchers mostly discuss on the blood pressure in pregnancy but 
to highlight the relationship between hypertension and kidney problem is also important. 
Hypertensive disorders usually resolve after delivery, but many recent studies show that 
hypertension is highly associated with End-Stage Renal Disease (Bellamy eta/., 2007; 
Mannis to et a!., 20 13 b). 
According to a study that conducted at the Institute of Medical Sciences, Banaras Hindu 
University, 1.39% patients with chronic hypertension had renal artery stenosis (Prakash 
et a/., 2006). Many recent studies show that hypertension is highly associated with 
cardiovascular disease and end-stage renal disease (Bellamy et al., 2007). The main 
secondary causes of chronic hypertension in pregnancy include coarctation of the aorta, 
renal artery stenosis , chronic kidney disease, and systemic disease with renal 
involvement (Lowe et a/., 20 15). Women with chronic hypertension are at high risk of 
developing preeclampsia which contribute end-stage renal failure later on (Relative 
Risk=4.3, 95% Confidence Interval=3.5-5.6) (Lowe eta/., 2015). 
The Odd Ratio for acute kidney injury (AKI) was 9.9 (95% CI 8.4-11.6) among women 
with chronic hypertension while 2.2 (95% CI 1. 7-2.9) among women with gestational 
hypertension. The largest expected population-attributable fractions were detected for 
eclampsia/severe preeclampsia tailed by chronic hypertension (OR: 10.7, 95o1o CI: 9.0-
2 
12.5) and the least for gestational hypertension (OR: 1.8, 95% CI: 0.9-2.8) (Kuklina et 
a/., 2009). Gilbert et a/ (2007) reported the relationship of chronic hypertension and 
severe complications during and after pregnancy. The complications include the 
cardiovascular disease and renal disease. A study conducted in Finland showed that the 
gestational hypertension women increase the risk of developing the kidney disease later 
on cotnpared to nonnotensive women (Hazard Ratio: 1.91, 95% CI: 1.18-3.09) ; the 
researchers also proved that chronic hypertension was the second highest percentage that 
getting CKD after 40 years follow up (Mannisto et al., 2013b). 
Hypertension in pregnancy is associated with renal complications (Asad and Garovic, 
2014). Asad and Garovic (2014) reported that hypertensive pregnancy disorders had 
significant 9.38 HR of deve1oping CKD and ESRD compared to those without 
hypertensive pregnancy disorders. Besides, women who previously had a hypertensive 
disorder pregnancy had a cardiovascular or renal disease in the average of six years (Asad 
and Garovic, 2014 ). In that case, treatment and further management for patient with 
hypertensive pregnancy disorders should be considered to prevent the consequences later 
on (Asad and Garovic, 2014). A study conducted at Swedish University Hospital reported 
that women with gestational hypertension had significantly increased the chance of 
getting microalbuminuria and chronic hypertension after seven years follow-up (Nisell et 
al., 1995). The presence of hypertension during pregnancy is also highly associated with 
renal disease (Nisell et al., 1995). 
3 
1.3 Pathogenesis of Kidney Disease in Hypertensive Pregnant Women 
The kidney plays an important part in the adaptive physiology of the pregnant woman, so 
it will presenting some renal function alterations found in hypertensive women (Machado 
et al.~ 2012). Hypertension is the most common medical complication of pregnancy and 
also can continue from pregnancy to postpartum. Pregnancy is a condition of chronic 
volume and sodium overload that leads to increased cardiac output, edema, and blood 
pressure elevation (Ghuman eta/., 2009). During delivery, accumulated sodiutn is rapidly 
reduced, and it may take up to two months for the salt and water homoeostasis to return 
to antepartum levels (Ghuman et a/., 2009). If patients have underlying conditions such 
as hypertension, kidney or heart disease, the pattern of physiologic return to the pre-
pregnant state may be impaired (Ghuman et al., 2009). 
Prakash et al. (2006) reported that renal function was normal in 25% of chronic 
hypertension patients while 9. 72% of chronic hypertension patients had a severe renal 
failure with serum creatinine more than 3 mg/dl. Most of the patients had mild renal 
insufficiency for chronic hypertension patients during pregnancy with four of seven 
patients had advanced renal failure required haemodialysis. The risk factors that favour 
an increased risk for renal progression for those who have essential hypertension was 
gout, a diuretic agent used, obesity and ageing (Johnson et a/., 2005). Women with 
hypertension disorders during pregnancy was significantly associated with the 
development CKD where the HR. was 9.3 of getting chronic kidney disease and ESRD 
compared to healthy women (Wang et al., 2013). 
An increase of SBP is related to greater chances of a fast decrease of renal function 
(Strevens, 2002; Shlipak eta/., 2005). Hanratty eta/. (20 11) reported that blood pressure 
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is associated with the incident ofCKD. For those who have SBP more than 120 mmHg 
will increase the risk of getting CKD (Hanratty et a/., 2011 ). Other than that, rapid 
declination of renal function was associated with the higher blood pressure (Vupputuri et 
a/., 2003). The cooperation of multidisciplinary team obstetricians and nephrologists is 
important to maintain the normal blood pressure in women with renal itnpairment and 
protect the kidney from further worsening (Taylor eta/., 2014). 
1.4 Prevalence of Kidney Disease 
The permanent loss of renal function is one of the major public health problem (Ong-
ajyooth eta/., 2009; Ingsathit eta/., 2010). The prevalence of kidney disease and ESRD 
is growing worldwide. In US, the estimated prevalence of CKD was 16.8% while 12.1-
17.5% in Asia (Hooi et a/., 2005). The incidence and prevalence of patients with ESRD 
had dialysis in Malaysia increased from 88 and 325 per million population (pmp) in 2001 
to 170 and 762 pmp in 2009 respectively (Hooi eta/., 2005). 
Malaysia is a prominent country in the world with diabetic nephropathy needing dialysis 
(Hooi eta/., 2005). In 2005, 15,000 patients were on dialysis and 2000 patients had a 
kidney transplant (Hooi eta/., 2005). 
1.5 Burden of Kidney Disease 
The rising number of ESRD causes an economic and social burden on the healthcare 
system. According to the Ministry of Health, based on economic calculation, the cost of 
dialysis was RM 2500 per month while it was 1. 7 times higher in the US for stage 3 and 
stage 4 CKD compared to stage 1 CKD. In Malaysia, the price increase by 2.6 times 
higher in patients with stage 4 CKD (Hooi et a/., 2005). 
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The burden of kidney disease is demonstrated by economic, social and medical aspects. 
The burden of kidney disease is not only life-threatening complications but significantly 
affects patients' quality of life (Karopadi et al., 2013 ). Diabetes is one of the factors that 
mainly contributes to the increasing incidence of ESRD accounting for 58% of new 
patients accepted for dialysis (Gob eta/., 2014). In Malaysia., frotn the year 1980-2002, 
the number of patients with transplant and dialysis approached 400 rates per million 
population (Hooi et al., 2005). Besides, the new dialysis case increased to 2,538 patients 
in 2004. 
Globally, the health care expenses per year for one person requiring dialysis are between 
$150,000-$200,000 and will exceed $1 tri1lion this decade. In developed countries like 
United Kingdom, US and Australia, only I% of the population needs dialysis or a 
transplant. However, they consume up to 5% of health care costs. The outcome of patient 
with dialysis is also poor, and the annual mortality exceeding 25% (Karopadi eta!., 2013 ). 
The total cost for haemodialysis is RM33,642 per patient for a year and RM 31,635 for 
peritoneal dialysis (Hooi et al., 2005). Annually, the amount ofhaemodialysis conducted 
reached 402 to 23,000 procedures per year while 70 to 2,300 for peritoneal dialysis per 
year (Hooi et a/., 2005). The mean cost for each haemodialysis treatment is RM 169 with 
the range from RM79.6l-RM475.79. For the peritoneal dialysis treatment, the range 
indicated from RM1,400-RM3,200 per month for one patient with the average of 
RM2, 186 (Hooi et a/., 2005). The mean of life years saved for haemodialysis is 10.96 
years and 5.21 years for peritoneal dialysis (Hooi eta/., 2005). The total cost per life year 
saved for both haemodialysis and peritoneal dialysis treatment is RM33.,642 and 
RM31 ,635 respectively (Hooi et al . ., 2005). The budget for equipment, property, 
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construction, expenses, and staff was higher for haemodialysis while the budget was 
higher on peritoneal dialysis for consumables and hospitalization (Hooi et a/., 2005). 
1.6 Justification of the Study 
This study highlights the importance of tnonitoring hypertension during and after 
postpartum period. No published study in Malaysia had been done on this topic yet. No 
study in Malaysia compares the creatinine clearance between gestational and chronic 
hypertension. There is only a study conducted in Malaysia by the Department of 
Obstetrics & Gynaecology, University of Malaya Medical Centre that compared the 
plasma creatinine and on underlying pathogenesis of preeclampsia and pregnancy-
induced hypertension (Y elumalai et a/., 20 I 0). Thus, this study provides some beneficial 
information regarding the creatinine clearance value on antenatal and postpartum 
hypertensive among patients in Hospital USM, Kubang Kerian. 
In this study, the pattern of declination of calculated creatinine clearance for non-
proteinuria patient was examined. This study was conducted to compare the creatinine 
clearance between patients with gestational hypertension and chronic hypertension at 
third trimester, six weeks postpartum, and 12 weeks postpartum. It provides more 
knowledge on postpartum hypertension and calculated creatinine clearance level that later 
help in identifying the relation of kidney problem and hypertension on top of improving 
the management of postpartum hypertensive in future. The consideration of taking renal 
function as the part of management of hypertensive pregnant as to prevent the long-term 
consequences especially CKD. Besides, this study also can help physicians to set the best 
timing in justifying further investigation and management for renal disease during 
postpartum especially on the duration of follow-up. The follow-up of hypertensive 
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disorders women after delivery is crucial to detect the complication and underlying 
disease and also to reduce the mortality and morbidity. Many researchers concentrated 
on hypertension during pregnancy and how to manage the patient with this complication 
preceding to delivery (Duley et a/., 2007) but the actual prevalence of hypertension after 
delivery is difficult to identify because of limited information or research on this problem. 
This matter was reported by the Confidential Enquiries into Maternal Deaths in the United 
Kingdom, where 10% of maternal deaths caused by hypertensive disorders of pregnancy 
was during postpartum period (Magee et al., 2005). The failure of obstetricians to link 
clear goals for follow-up after delivery in high risk patients are showed by the 50% failure 
rate (Webster et al., 2001 ). It is recommending to have multiple visits during two to six 
weeks after delivery depends on defining what is the reason to achieve for every visit 
(Webster et a/., 200 I). 
I. 7 Research Questions 
1. Is there any significant mean difference of calculated creatinine clearance levels 
within gestational and chronic hypertension based on three months follow-up 
when birth weight and gestational ages at delivery are controlled? 
2. Is there any significant mean difference of calculated creatinine clearance levels 
between gestational and chronic hypertension regardless of three months follow-
up when birth weight and gestational ages at delivery are controlled? 
3. Is there any significant mean difference of calculated creatinine clearance levels 
between gestational and chronic hypertension concerning three months follow-up 
when birth weight and gestational ages at delivery are controlled? 
8 
1.8 General Objective 
To compare the calculated creatinine clearance level between gestational and chronic 
hypertension in pregnant women. 
1. 9 Specific Objectives: 
1. To compare the mean of calculated creatinine clearance levels within gestational 
and chronic hypertension based on three months follow-up when birth weight and 
gestational ages at delivery were controlled. 
2. To compare the mean of calculated creatinine clearance levels between 
gestational and chronic hypertension regardless of three months follow-up when 
birth weight and gestational ages at delivery were controlled. 
3. To compare the mean of calculated creatinine clearance levels between 
gestational and chronic hypertension concerning three months follow up when 
birth weight and gestational ages at delivery were controlled. 
1 . 1 0 Research Hypotheses 
1. There is a significant mean difference of calculated creatinine clearance levels 
within gestational and chronic hypertension based on three months follow-up 
when birth weight and gestational ages at delivery were controlled. 
2. There is a significant mean difference of calculated creatinine clearance levels 
between gestational and chronic hypertension regardless of three months follow-
up when birth weight, gestational ages at delivery and length of diagnosed were 
controlled. 
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3. There is a significant mean difference of calculated creatinine clearance levels 
between gestational and chronic hypertension concerning three months follow-up 
when birthweight and gestational ages at delivery were controlled. 
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CHAPTER2 
LITERATURE REVIEW 
All the literature search related to gestational hypertension, chronic hypertension, serum 
creatinine level. creatinine clearance level and renal function test was widely done. Only 
articles in English were selected and the search engines used \vere PubMed. Science 
Direct, and Google Scholar. The keywords with the of used Boolean operators (AND/OR) 
were: "creatinine clearance" or "GFR" during "pregnancy" and "postpartum", ~'creatinine 
clearance" reduction or "GFR" from pregnancy to postpartum in chronic hypertension 
women and "creatinine clearance" or "GFR" reduction from pregnancy to postpartum in 
"gestational hypertension women'' or "pregnancy-induced hypertension''. All the 
literature search published from 2005 to 2015 were included. 
2. I. Hypertension in Pregnancy 
Hypertension is defined as SBP more than I 40 mm Hg and/or diastolic blood pressure 
more than 90 mm Hg during pregnancy (Prakash et al .• 2006). There is no longer known 
as hypertension when the DBP increase by 15 mmHg and SBP increase by 30 mmHg 
more than baseline BP if the entire values are still below 140/90 mmHg (Bavanandan et 
a/., 20I3). Table 2.1 shows the definition and classification of hypertension in pregnancy 
based on Malaysia Clinical Practice Guideline for management of hypertension. 
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Table 2.1 Definition and classification of hypertension in pregnancy 
Classification 
Chronic 
hypertension 
Preeclampsia-
eclampsia 
Superimposed 
preeclampsia 
Gestational 
hypertension 
Definition 
Hypertension is present before the conception or before 20th 
week of gestation or starting hypertension in late gestation but 
fails to resolve at postpartum 
It is detected in the hypertension after 20th week of gestation, 
and one or more of the following: 
• Significant proteinuria. 
• Renal insufficiency: serum creatinine more than 90 
micromol/1 or oliguria. 
• Liver disease 
• Neurological problems: convulsions (eclampsia) 
hyperreflexia with severe headaches or clonus, 
persistent visual turbulences (scotoma). 
• Haematological instabilities: thrombocytopenia, 
coagulopathy, haemolysis. 
• Fetal growth restriction. 
Diagnosed in women with chronic hypertension following this 
criteria: 
• Detected proteinuria after 20-week gestation 
• A sudden rise in the severity of hypertension 
• Presence of features of preeclampsia-eclampsia, 
• A sudden incline in proteinuria in women who have 
prior proteinuria early in gestation 
Hypertension diagnosed for the first time after 20 weeks of 
gestation. The definition is changed to "temporary" when blood 
pressure stabilizes at postpartum. 
Source: (Bavanandan et al., 20 1 3) 
2.2 Assessment for Hypertensive Pregnant Women 
Preeclampsia should be assessed in any woman with a new onset hypertension when 20 
weeks gestation. The assessment and management of this patient must be appropriate 
(Lowe et a/., 20 15). The urgent hospital admission should be considered if patients 
diagnosed preeclampsia have the threatening signs and symptoms of severe hypertension, 
epigastric pain, headache, nausea and vomiting (Vijgen eta/., 20 I 0). 
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At each investigation instead of diagnosing hypertension in pregnancy, the clinician 
should consider the woman's symptoms, laboratory investigations and foetal health 
(Lowe et a/., 20I5). Table 2.2 shows further laboratory investigation in hypertensive 
women during pregnancy. 
Table 2.2 The laboratory investigation in hypertensive wotnen during pregnancy 
Chronic 
Hypertension 
Gestational 
Hypertension 
Modality 
Assess for proteinuria 
Blood test for 
preeclampsia (FBC, 
electrolytes and creatinine, 
LFT) 
Assess for proteinuria 
Blood test for 
preeclampsia (FBC, 
electrolytes and creatinine, 
LFT} 
Source: (Lowe et al., 20I5) 
Frequency 
Each visit 
If rapid increase tn BP or new 
proteinuria 
At time of diagnosis: if non-protein 
uric repeat daily (ignore the 
assessment once proteinuria has been 
detected) 
Twice weekly or more regularly if 
unstable 
2.3 Management of Hypertension Disorders during Pregnancy 
Antihypertensive treatment should be on-going in all women with a systolic blood 
pressure of greater than or equal to 160mm Hg or a diastolic blood pressure greater than 
or equal to II 0 mm Hg (Lowe et a/., 20 I5). Hypertensive pregnant women should be 
brought up to an obstetrician for further investigation and management. 
The basic choices of the drug are stilllabetalol and methyldopa (Bavanandan eta/., 2013 ). 
Intravenous hydralazine or Intravenous labetalol or oral nifedipine are used in the 
occurrence of severe hypertensive crisis to lower the BP in pregnant women. Otherwise, 
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to reduce the risk of severe gestational hypertension, 1.5 g/day of high calcium 
supplement can be taken (Bavanandan et a/., 2013 ). 
Among chronic hypertension women, a preconception psychotherapy and regulation of 
treatment should be done. They may require an adjustment in the type of anti-
hypertensive drug used before pregnancy. Drugs like Angiotensin II receptor blockers 
(ARB), Angiotensin converting enzyme (ACE), and thiazide diuretics are related to foetal 
abnormality so that they are contraindicated in pregnancy (Bavanandan et a/., 2013 ). 
Patients with hypertensive disorder are suggested to bed rest in order to accelerate the 
uterine blood flow and stimulate nutrition to the foetus. The sitting position is the 
recommended position for outpatient blood pressure checking (Shah, 2007). Table 2.3 
until table 2.5 show the antihypertensive drug treatment used in pregnancy and 
postpartum, dose and side effects. 
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Table 2.3 Guidelines for selecting antihypertensive drug treatment in pregnancy 
Drug Dose Action Contra- Practise Points 
indications 
Methyldopa 250-750mg Central Depression Slow onset of action 
tds over 24H, dry mouth, 
75-300Jlg tds depression, sedation, 
blurred vision 
Clonidine Withdrawal effects: 
rebound hypertension 
Labetalol 100-400mg p Blocker Asthma, Bradycardia, 
q8h with mild chronic bronchospasm, 
alpha auways headache, nausea, scalp 
vasodilator limitation tingling (resolves within 
effect 24H) 
Oxprenolol 20-160rng 
q8h 
Nifedipine 20mg-60mg Ca channel Aortic stenosis Severe headache in first 
slow release antagonist 24 hours 
bd Flushing, tachycardia, 
peripheral oedetna, 
constipation 
Prazosin 0.5-5 rng q8h a blocker Orthostatic 
Hypotension 
(especially after first 
dose) 
Hydralazine 25-50 mg Vasodilator - Flushing, headache, 
q8h nausea, lupus-like 
syndrome 
Source: (Lowe et a/., 20 15) 
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Table 2.4 The most frequently used agents to stabilize blood pressure 2:: 160/110 mmHg 
Agent Dose Onset Peak Duration 
Labetalol Start with 20 mg IV; 5 min 30 4hr 
Repeat 20 to 80 mg IV min 
q 30 min, or 1 to 2 mg/min, max 300 mg 
(then switch to oral) 
Nifedipine 5 to 10 mg capsule to be swallowed, or 5 to 10 30 ::::6 hr 
bitten then swallowed, every 30 min m1n 
Hydralazine Start with 5mg IV; repeat 5 to 10 mg IV 5 min 
every 30 min, or 0.5 to I 0 mg/hr IV, to a 
maximum of 20 mg IV (or 30 mg IM) 
Source: (Benton eta/., 2011; Bavanandan et al., 2013) 
Table 2.5 The drug used for postpartum hypertension 
Labetalol Hydralazine 
Dose I OOmg bd (oral): 200-300J.Lg/min iv 
Side-effects 
20mg/h iv infusion, infusion: 
doubled every 30min: maintenance dose 
max 2.4g daily (oral) 50-150 Jlg/min iv 
or 160mg/h iv infusion 
infusion 
Postural hypotension, 
Dizziness, tiredness, 
headache, rashes, 
scalp tingling, 
difficulty in 
micturition, 
gastrointestinal 
symptoms, liver 
damage 
Headaches, nausea, 
sweating, 
arrhythmias, 
precipitation of 
angina, anxiety, 
restlessness, hyper-
reflexia 
Safe in Yes Yes (but monitor 
infant) breastfeeding 
Source: (Chandiramani et al., 2007) 
min 
30 
min 
Nifedipine 
l 0 mg bd orally, 
adjusted according to 
response to a 
maximum dose of 
60mg daily in 
divided doses 
Tachycardia, 
palpitations, 
dizziness, flushing, 
headache, rash, 
pruritus, urticarial, 
nausea, diarrhoea, 
constipation, eye 
pain, depression 
Yes 
The timing of delivery at 37 weeks of gestation and above among gestational 
hypertension women shou1d be discussed by the physician. But there is no enough 
evidence to make a suggestion to deliver Jess than 3 7 weeks of gestation for women with 
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gestational hypertension unless they are diagnosed to have preeclampsia (Magee et at., 
2014). Meanwhile, chronic hypertension women who had no complication and healthy at 
37 weeks of gestation and above should be considered to deliver at 38 to 39 weeks of 
gestation (Magee et a/., 2014 ). Vaginal delivery should be considered for women with 
hypertension during pregnancy, but caesarean delivery is compulsory when there is 
obstetric cotnplications (Magee et a/., 2014). The use of ripening agents with 
prostaglandins makes the vaginal delivery more possible (Shah, 2007). 
2.4 Management of Hypertension Disorders during Postpartum 
Hypertensive disorder women are advised to have their blood pressure frequently checked 
at a local clinic if there is a delay in their hospital appointment. The dose of the 
antihypertensive drug should be slowly decreased and not suddenly stop for these patients 
(Bavanandan et a/., 2013). For women with gestational hypertension, the 
antihypertensive drug is given approximately one week at postpartum (Bavanandan et a/., 
2013 ). Women with chronic hypertension will need a long duration of antihypertensive 
treatment in pregnancy and blood pressure usually start to normalize six weeks after 
delivery (Lowe et a/., 2015). Women with unstable blood pressure and established 
hypertension after delivery may require a medication tuning. Besides, non-steroidal 
inflammatory drugs should not be given if the hypertension is difficult to control during 
postpartum because of the occurrence of AKI or CKD, or thrombocytopenia (Lowe eta/., 
20 15). Meanwhile, not all the established hypertension women will require treatment 
during pregnancy. Basically, for those who have the highest risk of preterm labour and 
multiparous women will need treatment because of the elevation of the serum urate 
concentration (Lowe et al .. 2015). 
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It is important to follow-up the patients after six weeks to make sure determination or 
resolution of pregnancy-related changes and further ongoing care needed. It is advisable 
to follow-up the high-risk patients within three to six months (Julius eta/., 2006). This 
care included further investigation and management of renal disease (Lowe et a/., 20 15). 
It is also important to ensure normalization of blood pressure during postpartum in 
women with uncertain blood pressure control before pregnancy (Lowe et a!., 20 15). 
Women with persistent hypertension not previously assessed should undergo routine 
work-up according to standard regimens (Lowe eta/., 2015). 
2.5 Renal Function in Hypertensive Pregnant Women 
A serum creatinine determination for creatinine clearance estimation is very important to 
screen renal disease (Snyder and Pendergraph, 2005). A laboratory tests used to evaluate 
and 1nonitor organ function over time during pregnancy are urine volutne, creatinine, 
protein in the urine, and albumin (Magee et a/., 2014 ). Department of Obstetrics & 
Gynaecology, University of Malaya Medical Center reported the results on the renal 
function among hypertensive disorder women at the early pregnancy, late pregnancy and 
six weeks of postpartum. There were a significant mean differences of plasma creatinine 
between pre-eclampsia and normal pregnant women in all three measurements. There was 
also a significant mean difference of plasma creatinine between pregnancy-induced 
hypertension and normal pregnant women during late pregnancy (Y elumalai eta/., 20 I 0). 
Based on a study conducted in Sweden, the creatinine clearance was significantly higher 
in women with preeclampsia compared to women with gestational hypertension 
(Strevens, 2002). 
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Parity does affect the renal function due to increase age and comorbid of the maternal 
(Wang eta/., 2011 ). For women who delivered at age more than 30 years had significantly 
increased the HR of chronic renal failure by 2.52 compared to women who delivered at 
age 25 years (Kuo et a/., 20 I 2 ). The increasing age at the frrst birth will increase the risk 
of chronic renal failure death (Kuo eta/., 2012). In five cohort study population, older 
wotnen have less schooling and higher parity because of educated women are likely to 
delay pregnancy for career reasons (Fall eta/., 2015). Many underlying diseases like 
hypertension, diabetes and obesity were associated complication during pregnancy in 
older women (Fall et al., 20 15). Baby birth weight is one of the associated factors of 
decreasing the renal function and increase the risk of end stage renal disease. Women 
with pretenn birth low birthweight increase the risk of getting end stage renal disease 
(Wang eta/., 2013; Wu et al., 2014). It was also reported that the blood pressure levels 
during common pregnancy is associated with gestational age, race, BMI and parity 
(Strevens, 2002). 
2.6 Creatinine Clearance during Pregnancy 
Pregnancy is related to the changes in the hormone that affects the renal function. 
Creatinine clearance will increase in pregnancy due to the increase of ultrafiltration 
capacity and reduced of average colloid osmotic pressure (Hussein and Lafayette, 2014 ). 
The kidneys size will increase up to 1 em during pregnancy, and the most remarkable 
changes can be found in the urinary tract (Podymow and August, 2007). The changes of 
renal hemodynamic can be seen at the end of the first trimester when both GFR and renal 
plasma flow increase by 50% (Podymow and August, 2007). Measurement of kidney 
function and proteinuria are the most important and act as early standard detection of 
subclinical pathology in recognizing the renal disease. The choice of tnedications and the 
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changes of hormone and hemodynamic changes in pregnancy must be considered to 
assess renal function in pregnancy (Maynard and Thadhani, 2009). The normal value of 
serum creatinine (umol/L) during the third trimester of pregnancy is in the range 35 to 80 
(Brenner, 2004). 
The level of GFR usually will increase during pregnancy due to the decrease in serum 
creatinine concentration. The average falls by 0.4 mg/dl to a pregnancy range of0.4-0.8 
mg/dl (Fischer, 2007). Hence, although a serum creatinine of 1.0 mg/dl is a normal range 
for non-pregnant woman, it reveals the renal damage in a pregnant woman (Maynard and 
Thadhani, 2009). During pregnancy, creatinine clearance was found 40% higher 
compared with non-pregnant women (Hussein and Lafayette, 2014). Then, it will decline 
to normal non-pregnant level one month after delivery (Hussein and Lafayette, 2014). 
The renal plasma flow and creatinine clearance will change because of the exceeding 
renal plasma flow compared to the creatinine clearance in the early pregnancy (Hussein 
and Lafayette, 2014). The filtration fraction is slightly lower in non-pregnant controls 
(Hussein and Lafayette, 2014). The renal plasma flow falls toward non-pregnant levels 
between week 12 and third trimester while the creatinine clearance will usually normalize 
after 4-6 weeks postpartum (Odutayo and Hladunewich, 2012). Figure 2.1 shows the 
trend of GFR, RPF and FF during and post-delivery in normal pregnant women. 
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Figure 2.1 GFR, RPF and FF trends in normal pregnant women from pregnancy to 
postpartum (GFR, glomerular filtration rate; RPF, renal plasma flow; FF, filtration 
fraction) 
Source: (Odutayo and Hladunewich, 2012) 
2. 7 Physiology of Hypertensive Disorder during Pregnancy 
The important of monitoring the patients with chronic hypertension in pregnancy is 
because they have the higher incidence of getting the superimposed preeclampsia. Thus, 
the prospective studies of chronic hypertensive may be helpful in clarifying early 
complication which are important in the pathophysiology of preeclampsia. In most 
women with chronic hypertension, creatinine clearance is normally increase during 
pregnancy, but will decrease when superimposed preeclampsia is developed (Roberts et 
al. , 2009). 
In women with pregnancy-induced hypertension, the creatinine clearance level will 
slightly decrease during pregnancy compared to normal pregnancy (Odutayo and 
Hladunewich, 20 12). Meanwhile, the creatinine clearance was significantly low to 91 
ml/min in women with preeclampsia compared to a value of 148 mJ/min in healthy 
women (Odutayo and Hladunewich, 2012). This reduction is because of two phenomena. 
The first is because of the low protein concentration in plasma that enters the glomerular 
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microcirculation and the second is because of the renal plasma flow elevation (Odutayo 
and Hladunewich, 2012). 
2.8 Pathogenesis of Kidney Disease in Hypertensive Pregnant Women 
The kidney plays an important part in the adaptive physiology of the pregnant wotnan, so 
it will presenting some alterations found in hypertensive women (Machado eta/., 2012). 
Hypertension is the most common medical complication of pregnancy and also can 
persevere from pregnancy to postpartum. Pregnancy is a condition of chronic volume and 
sodium overload that leads to increased cardiac output, oedema, and blood pressure 
elevation (Ghuman eta/., 2009). During delivery, accumulated sodium is rapidly reduced, 
and it may take up to 2 months for the salt and water homoeostasis to return to antepartum 
levels (Ghuman eta/., 2009). If patients have underlying conditions such as hypertension, 
kidney or heart disease, the pattern of physiologic return to the pre-pregnant state may be 
impaired (Ghuman et a/., 2009). Prakash et a/. (2006) reported that renal function was 
normal in 25% of chronic hypertension patients while 9. 72% of chronic hypertension 
patients had a severe renal failure with serum creatinine more than 3 mg/dl. 
Most of the patients had mild renal insufficiency for chronic hypertension patients during 
pregnancy with four of seven patients had advanced renal failure required haemodialysis. 
The risk factors that favour an increased risk for renal progression for those who have 
essential hypertension was gout, a diuretic agent used, obesity and ageing (Johnson eta!., 
2005). Women with hypertension disorders during pregnancy was significantly 
associated with the development CKD where the HR was 9.3 of getting CKD and ESRD 
compared to healthy women (Wang eta/., 2013). The cooperation of multidisciplinary 
team obstetricians and nephrologists is important to maintain the normal blood pressure 
22 
in women with renal impairment and protect the kidney from further worsening (Taylor 
eta/., 2014). 
An increase of SBP is related to greater chances of a fast decrease of renal function 
(Strevens. 2002; Shlipak et al.. 2005). Hanratty eta/. (20 II) reported that blood pressure 
is associated with the incident ofCKD. For those who have SBP more than 120 mmHg 
will increase the risk of getting CKD (Hanratty et al., 2011). Other than that, one study 
found that those who was higher treated blood pressure was related to prompt renal 
function decline (Vupputuri et a/., 2003 ). 
2.9 Calculation of Creatinine Clearance 
Serum creatinine level and creatinine clearance tests are used to indicate renal function. 
The rate of creatinine clearance is the indication of the kidneys' ability to filter the blood. 
The decrease value of creatinine clearance shows the poor renal function (Brenner, 2004). 
There are two main methods of creatinine tests to measure kidney function (Brenner, 
2004): 
• 
Creatinine clearance can be accurately determined by assessing the amount of 
creatinine present in a sample of urine collected over 24 hours. This method needs 
a person to urinate completely in a container for one day to test for the amount of 
creatinine in the urine. This method is inconvenient to assess the creatinine 
clearance, but it may be necessary to diagnose some kidney conditions. 
• GFR can be estimated using only blood level of creatinine, which is calculated by 
using a formula. Different formulas are available, which take into account 
age, sex, and sometimes weight and ethnicity. The higher the blood creatinine 
level, the lower the estimated GFR and creatinine clearance. 
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For practical reasons, the blood test estimation method for GFR is used far more often 
than the 24-hour urine collection test for creatinine clearance. The calculated creatinine 
clearance is also a good estimate of GFR, but it becomes imprecise when a patient's body 
mass is considerably outside the normal range (for example, morbid obesity or severe 
malnutrition) or when renal function is very decreased (i.e. GFR <20 mL/min). In this 
study, Modification of Diet in Renal Disease (MDRD) fonnula was used because it was 
more convenience and practical to apply compare to measured creatinine clearance 
(Brenner, 2004 ). It is a standard clinical method to estimates GFR using a combination 
of serum markers and clinical parameters (Maynard and Thadhani, 2009). The formula 
for MDRD eGFR is calculated in ml/min/1.73m2 (Maynard and Thadhani, 2009): 
175 x (Serum Creatinine/ 88.4Yt. 154 x (Aget0·203 x (0.742 iffemale) 
2.1 0 Conceptual Fratnework 
Figure 2.2 shows the conceptual framework of this study. Calculated creatinine clearance 
of participants with gestational and chronic hypertension were evaluated at third 
trimester, six weeks postpartum and 12 weeks postpartum. 
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